Drug

Cisplatin

In clinical development

Actively researchedLate-stage developmentRising momentum

Also known as (SP-4-2)-DIAMMINEDICHLOROPLATINUM, CDDP, CIS-DIAMMINEDICHLOROPLATINUM, CIS-DIAMMINEDICHLOROPLATINUM II+16 more

(SP-4-2)-DIAMMINEDICHLOROPLATINUM, CDDP, CIS-DIAMMINEDICHLOROPLATINUM, CIS-DIAMMINEDICHLOROPLATINUM II, Cis-DDP, DDP, Diaminedichloroplatinum, Peyrone's Salt, Platinol, cis-Diaminedichloroplatinum, cis-Platinum II, cis-Platinum compound, cis-diamminedichloroplatinum(II), Cisplantin, Cisplatine, cisplatino, Cis-platinum, Cisplatinum, PLATINUM, DIAMMINEDICHLORO-, (SP-4-2)-, Peyrone's Chloride.

RxNorm2555 ChEMBLCHEMBL11359 ATCL01XA01UNIIQ20Q21Q62J

Research papers

Active clinical trials

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared With Standard of Care as First-line Intervention in Participants With Metastatic Esophageal Carcinoma.

Clinical trial2026-07-20Results posted · ClinicalTrials.gov

Clinical trial2026-07-20Status changed to Completed · ClinicalTrials.gov

A Phase III Randomized Trial of Pembrolizumab in Combination With Sacituzumab Govitecan-hziy vs Standard of Care in Anti-PD(L)1-Resistant Advanced Urothelial Cancer

Clinical trial2026-07-20Results expected Q4 2028 · ClinicalTrials.gov

SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression

Clinical trial2026-07-20Results expected Q4 2027 · ClinicalTrials.gov

A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody), Cemiplimab (Anti-PD-1 Antibody), and Chemotherapy Versus Cemiplimab and Chemotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Irrespective of PD-L1 Expression Levels

Clinical trial2026-07-15Results expected Q1 2030 · ClinicalTrials.gov

Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in the Treatment of Esophageal Small Cell Carcinoma: a Single-arm, Multicenter, Phase II Clinical Study

Clinical trial2026-07-13Primary completion · ClinicalTrials.gov

Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial

Clinical trial2026-07-10Results expected Q3 2028 · ClinicalTrials.gov

Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing

Clinical trial2026-07-10Results expected Q4 2027 · ClinicalTrials.gov

Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i>-Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer.

Research2024-08-22Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Gamma entrainment using audiovisual stimuli alleviates chemobrain pathology and cognitive impairment induced by chemotherapy in mice.

Research2024-03-06Science translational medicine

Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.

Research2024-03-01The New England journal of medicine

Comparative analysis between 2D and 3D colorectal cancer culture models for insights into cellular morphological and transcriptomic variations.

Research2023-10-26Scientific reports

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Cisplatin

Aliases & brands

(SP-4-2)-DIAMMINEDICHLOROPLATINUMCDDPCIS-DIAMMINEDICHLOROPLATINUMCIS-DIAMMINEDICHLOROPLATINUM IICis-DDPDDPDiaminedichloroplatinumPeyrone's SaltPlatinolcis-Diaminedichloroplatinumcis-Platinum IIcis-Platinum compoundcis-diamminedichloroplatinum(II)CisplantinCisplatinecisplatinoCis-platinumCisplatinumPLATINUM, DIAMMINEDICHLORO-, (SP-4-2)-Peyrone's Chloride

RxNorm CUI

2555

ChEMBL ID

CHEMBL11359

ATC codes

L01XA01

UNII

Q20Q21Q62J

Clinical trials

194 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

194

registered trials across all phases

LATEST COMPLETION 2026

Active studies

Recruiting

Late-stage (III+)

Completed

Discontinued

PHASE DISTRIBUTIONn = 194

Early Phase 11Phase 122Phase 1 / 211Phase 294Phase 2 / 37Phase 354Phase 41Phase N / A4

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Multicenter Comparative of Toxicity and Effectiveness of Lobaplation or Cisplatin Based Adjuvant Chemotherapy in Esophageal Carcinoma

CompletedPH IVHenan Cancer Hospitaln=7332018

Active, not recruitingPH II/IIIRegeneron Pharmaceuticalsn=1602031

A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Participants With Muscle-invasive Bladder Cancer (MIBC) (KEYNOTE-992)

Active, not recruitingPH IIIMerck Sharp & Dohme LLCn=5202031

A Prospective, Multicenter, Randomized Controlled Phase 3 Clinical Trial Comparing Postoperative Adjuvant Cisplatin Concurrent Chemoradiotherapy With Adjuvant Radiotherapy Alone for Intermediate-risk Head and Neck Squamous Cell Carcinoma

RecruitingPH IIISun Yat-sen Universityn=3862031

Phase III Multicenter Randomized Controlled Trial of PD-1 Inhibitor Combined With Preoperative Concurrent Chemoradiotherapy and Surgery for Locally Advanced Esophageal Squamous Cell Carcinoma (NEOCRTEC2101)

RecruitingPH IIISun Yat-sen Universityn=4222031

Recent completions

Trials that read out recently, adding to the completed evidence base.

Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment

CompletedPH IIINational Cancer Institute (NCI)n=2362026

Phase II Study Evaluating HPV-16 Vaccination (ISA101b) and Pembrolizumab Plus Cisplatin Chemoradiotherapy for "Intermediate Risk" HPV-16 Associated Head and Neck Squamous Cell Carcinoma (HNSCC)

CompletedPH IIDan Zandbergn=182026

A Randomized, Double-Blind, Phase 3 Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy as First Line Treatment for Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)

CompletedPH IIIMerck Sharp & Dohme LLCn=7392026

A Multicenter, Prospective, Double-Cohort Phase II Clinical Study of Camrelizumab in Combination With Docetaxel and Platinum or Apatinib Mesylate as First-Line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

CompletedPH IIShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong Universityn=812025

A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Etoposide and Cisplatin or Carboplatin for the First-Line Treatment of Participants With Extensive-Stage Small Cell Lung Cancer (KEYNOTE-B99)

CompletedPH IIMerck Sharp & Dohme LLCn=1262025

A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants With Advanced and/or Unresectable Biliary Tract Carcinoma

CompletedPH IIIKey trialMerck Sharp & Dohme LLCn=1,0692025

Research activity

43 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time

19942024

Most influential

Platinum-based chemotherapy plus cetuximab in head and neck cancer.

The New England journal of medicine · 2008 · 2,492 cites

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

The New England journal of medicine · 2014 · 2,470 cites

Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.

The New England journal of medicine · 2003 · 2,008 cites

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

The New England journal of medicine · 2003 · 1,909 cites

Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2000 · 1,560 cites

Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations.

Cancer · 1994 · 1,539 cites

Related diseases

12 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Active research areas

Lung Neoplasms7 Carcinoma, Non-Small-Cell Lung6 Stomach Neoplasms4 Urinary Bladder Neoplasms4 Adenocarcinoma3 Carcinoma, Squamous Cell3 Carcinoma, Transitional Cell3 Esophageal Neoplasms3 Neoplasm Invasiveness3 Uterine Cervical Neoplasms3 Neoplasm Metastasis2 Neoplasm Recurrence, Local2

Related drugs

8 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Fluorouracil

Studied across 17 of the same disease areas as Cisplatin in the shared literature.

17 shared diseases8 shared papers

Carboplatin

Studied across 16 of the same disease areas as Cisplatin in the shared literature.

16 shared diseases8 shared papers

Pembrolizumab

Studied across 18 of the same disease areas as Cisplatin in the shared literature.

18 shared diseases5 shared papers

Gemcitabine

Studied across 11 of the same disease areas as Cisplatin in the shared literature.

11 shared diseases7 shared papers

Deoxycytidine

Studied across 9 of the same disease areas as Cisplatin in the shared literature.

9 shared diseases5 shared papers

Paclitaxel

Studied across 13 of the same disease areas as Cisplatin in the shared literature.

13 shared diseases3 shared papers

Camptothecin

Studied across 15 of the same disease areas as Cisplatin in the shared literature.

15 shared diseases2 shared papers

Atezolizumab

Studied across 10 of the same disease areas as Cisplatin in the shared literature.

10 shared diseases2 shared papers

References & data sources

RxNorm (U.S. National Library of Medicine) — drug identity
ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
Europe PMC — research literature
ClinicalTrials.gov — clinical trials